| 001 | 300769 | ||
| 005 | 20251010125424.0 | ||
| 024 | 7 | _ | |a 10.1016/j.eururo.2025.04.017 |2 doi |
| 024 | 7 | _ | |a pmid:40318933 |2 pmid |
| 024 | 7 | _ | |a 0302-2838 |2 ISSN |
| 024 | 7 | _ | |a 1421-993X |2 ISSN |
| 024 | 7 | _ | |a 1873-7560 |2 ISSN |
| 024 | 7 | _ | |a altmetric:176729374 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2025-00917 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Karpinski, Madeleine J |0 P:(DE-HGF)0 |b 0 |
| 245 | _ | _ | |a Updated Prostate Cancer Risk Groups by Prostate-specific Membrane Antigen Positron Emission Tomography Prostate Cancer Molecular Imaging Standardized Evaluation (PPP2): Results from an International Multicentre Registry Study. |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2025 |b Elsevier Science |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1760093628_11806 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a Volume 88, Issue 5, November 2025, Pages 484-495 |
| 520 | _ | _ | |a We established prognostic nomograms incorporating prostate-specific membrane antigen (PSMA) positron emission tomography (PET) parameters standardised by Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE; PPP1). Here, we develop an updated PPP2 risk score from a large international multicentre registry study.We included 6128 prostate cancer patients who underwent PSMA-PET at 20 hospitals in Europe, USA, and Australia between 2013 and 2022. Investigator sites were split 2:1 into the development (4044 patients) and validation (2084 patients) cohorts. We created nomograms of version 2 (PPP2) based on Cox regression models with the least absolute shrinkage and selection operator penalty for overall survival (development cohort). Performance of both nomograms was measured using Harrell's C-index and calibration plots and a head-to-head comparison with the National Comprehensive Cancer Network (NCCN) risk score by receiver operating characteristic curves (validation cohort).Predictors were distant metastases (extrapelvic nodal metastases [M1a], bone metastases [M1b], and visceral metastases [M1c]), PSMA expression score, and total lesion count (visual PPP2) or total tumour volume (quantitative PPP2). C-indices (95% confidence interval) in the validation cohort were 0.80 (0.78-0.82; visual) and 0.80 (0.79-0.82; quantitative), respectively. Accuracy of both the PPP2 nomograms was superior to the NCCN risk score (n = 1034, area under the curve 0.84 vs 0.76; p < 0.001). The retrospective design represents a limitation of the study.PPP nomograms were improved in an international multicentre study to predict accurately the 3- and 5-yr overall survival probabilities of prostate cancer. PPP2 yielded superior accuracy to the NCCN risk score. A free software tool has been created for PROMISE and PPP2 assessments (promise-pet.org). |
| 536 | _ | _ | |a 899 - ohne Topic (POF4-899) |0 G:(DE-HGF)POF4-899 |c POF4-899 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Overall survival |2 Other |
| 650 | _ | 7 | |a Prognosis |2 Other |
| 650 | _ | 7 | |a Prostate Cancer Molecular Imaging Standardized Evaluation nomogram |2 Other |
| 650 | _ | 7 | |a Prostate cancer |2 Other |
| 650 | _ | 7 | |a Prostate-specific membrane antigen positron emission tomography |2 Other |
| 700 | 1 | _ | |a Rahbar, Kambiz |b 1 |
| 700 | 1 | _ | |a Bögemann, Martin |b 2 |
| 700 | 1 | _ | |a Nikoukar, Laya Rahbar |b 3 |
| 700 | 1 | _ | |a Schäfers, Michael |b 4 |
| 700 | 1 | _ | |a Hoberück, Sebastian |b 5 |
| 700 | 1 | _ | |a Miederer, Matthias |b 6 |
| 700 | 1 | _ | |a Hölscher, Tobias |b 7 |
| 700 | 1 | _ | |a Rasul, Sazan |b 8 |
| 700 | 1 | _ | |a Miszczyk, Marcin |b 9 |
| 700 | 1 | _ | |a Lanfranchi, Francesco |b 10 |
| 700 | 1 | _ | |a Bauckneht, Matteo |b 11 |
| 700 | 1 | _ | |a Pfob, Christian H |b 12 |
| 700 | 1 | _ | |a Kind, Felix |b 13 |
| 700 | 1 | _ | |a Goffin, Karolien |b 14 |
| 700 | 1 | _ | |a Hüsing, Anika |b 15 |
| 700 | 1 | _ | |a Kesch, Claudia |b 16 |
| 700 | 1 | _ | |a Herrmann, Ken |0 P:(DE-HGF)0 |b 17 |
| 700 | 1 | _ | |a Stuschke, Martin |b 18 |
| 700 | 1 | _ | |a Gafita, Andrei |b 19 |
| 700 | 1 | _ | |a Hüsing, Johannes |b 20 |
| 700 | 1 | _ | |a Calais, Jeremie |b 21 |
| 700 | 1 | _ | |a Hofman, Michael S |b 22 |
| 700 | 1 | _ | |a Hope, Thomas A |b 23 |
| 700 | 1 | _ | |a Miksch, Jonathan |b 24 |
| 700 | 1 | _ | |a Soeterik, Timo F W |b 25 |
| 700 | 1 | _ | |a Di Giorgio, Andrea |b 26 |
| 700 | 1 | _ | |a Farolfi, Andrea |b 27 |
| 700 | 1 | _ | |a Bjartell, Anders |b 28 |
| 700 | 1 | _ | |a Trägårdh, Elin |b 29 |
| 700 | 1 | _ | |a Unterrainer, Lena M |b 30 |
| 700 | 1 | _ | |a Holzgreve, Adrien |b 31 |
| 700 | 1 | _ | |a Sheikh, Gabriel T |b 32 |
| 700 | 1 | _ | |a Rauscher, Isabel |b 33 |
| 700 | 1 | _ | |a Eiber, Matthias |b 34 |
| 700 | 1 | _ | |a Hadaschik, Boris A |b 35 |
| 700 | 1 | _ | |a Fendler, Wolfgang P |0 P:(DE-HGF)0 |b 36 |
| 773 | _ | _ | |a 10.1016/j.eururo.2025.04.017 |g p. S0302283825002490 |0 PERI:(DE-600)1482253-2 |n 5 |p 484-495 |t European urology |v 88 |y 2025 |x 0302-2838 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:300769 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 17 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 36 |6 P:(DE-HGF)0 |
| 913 | 1 | _ | |a DE-HGF |b Programmungebundene Forschung |l ohne Programm |1 G:(DE-HGF)POF4-890 |0 G:(DE-HGF)POF4-899 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-800 |4 G:(DE-HGF)POF |v ohne Topic |x 0 |
| 914 | 1 | _ | |y 2025 |
| 915 | _ | _ | |a National-Konsortium |0 StatID:(DE-HGF)0430 |2 StatID |d 2024-12-20 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EUR UROL : 2022 |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2024-12-20 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2024-12-20 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2024-12-20 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2024-12-20 |
| 915 | _ | _ | |a IF >= 20 |0 StatID:(DE-HGF)9920 |2 StatID |b EUR UROL : 2022 |d 2024-12-20 |
| 920 | 1 | _ | |0 I:(DE-He78)ED01-20160331 |k ED01 |l DKTK Koordinierungsstelle Essen/Düsseldorf |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)ED01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::